Objective  To understand the research status and hotspots of the literature related to colorectal cancer organoid, and explore the development trends in this field.

Methods  Literature related to colorectal cancer organoid published in CNKI, WanFang Data, VIP and Web of Science Core Collection (WoSCC) from 2014 to 2023 was collected, and the CiteSpace 6.1.R6 software was used to analyze the countries, institutions, references and keywords of the included literature.

Results  There were 21 Chinese articles in this field. Due to the limited number, they were not used for visualization analysis. A total of 733 English articles were included. The annual number of publications showed an overall upward trend. The largest number of publications were published by the United States (n=241), followed by China (n=175). The cooperation distribution of issuing institutions was regional. According to the keywords analysis, the domestic research hotspots mainly focused on 3D culture, tumorigenesis and precision medicine, while the foreign ones were precision medicine, drug screening and stem cell. Self renewal, proliferation, and drug screening were the words that continue to emerge in the domestic English articles, whereas tumor heterogeneity, patient derived organoid and tumor microenvironment were the ones in foreign English articles.

Conclusion  There were few Chinese studies in this field, which were in the initial stage. The number of English publications increased rapidly. The cross-regional and high-quality cooperation should be strengthened in the future. The studies in China mainly focued on basic research, and gradually turned to clinical application research. To establish and improve the co-culture model of colorectal cancer organoid and tumor microenvironment may be the research trend in the future.

1.Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. DOI: 10.3322/caac.21834.

2.Liu L, Yan Q, Chen Z, et al. Overview of research progress and application of experimental models of colorectal cancer[J]. Front Pharmacol, 2023, 14: 1193213. DOI: 10.3389/fphar.2023.1193213.

3.Katsiampoura A, Raghav K, Jiang ZQ, et al. Modeling of patient-derived xenografts in colorectal cancer[J]. Mol Cancer Ther, 2017, 16(7): 1435-1442. DOI: 10.1158/1535-7163.MCT-16-0721.

4.Pergolini I, Morales-Oyarvide V, Mino-Kenudson M, et al. Tumor engraftment in patient-derived xenografts of pancreatic ductal adenocarcinoma is associated with adverse clinicopathological features and poor survival[J]. PLoS One, 2017, 12(8): e0182855. DOI: 10.1371/journal.pone.0182855.

5.Goto T. Patient-derived tumor xenograft models: toward the establishment of precision cancer medicine[J]. J Pers Med, 2020, 10(3): 64. DOI: 10.3390/jpm10030064.

6.Byrne AT, Alférez DG, Amant F, et al. Interrogating open issues in cancer medicine with patient-derived xenografts[J]. Nat Rev Cancer, 2017, 17(10): 632. DOI: 10.1038/nrc.2017.85.

7.Sato T, Stange DE, Ferrante M, et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium[J]. Gastroenterology, 2011, 141(5): 1762-1772. DOI: 10.1053/j.gastro.2011.07.050.

8.Drost J, van Jaarsveld RH, Ponsioen B, et al. Sequential cancer mutations in cultured human intestinal stem cells[J]. Nature, 2015, 521(7550): 43-47. DOI: 10.1038/nature14415.

9.Velasco V, Shariati SA, Esfandyarpour R. Microtechnology-based methods for organoid models[J]. Microsyst Nanoeng, 2020, 6: 76. DOI: 10.1038/s41378-020-00185-3.

10.Weeber F, van de Wetering M, Hoogstraat M, et al. Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases[J]. Proc Natl Acad Sci USA, 2015, 112(43): 13308-13311. DOI: 10.1073/pnas.1516689112.

11.Fujii M, Shimokawa M, Date S, et al. A colorectal tumor organoid library demonstrates progressive loss of niche factor requirements during tumorigenesis[J]. Cell Stem Cell, 2016, 18(6): 827-838. DOI: 10.1016/j.stem.2016.04.003.

12.Boos SL, Loevenich LP, Vosberg S, et al. Disease modeling on tumor organoids implicates AURKA as a therapeutic target in liver metastatic colorectal cancer[J]. Cell Mol Gastroenterol Hepatol, 2022, 13(2): 517-540. DOI: 10.1016/j.jcmgh.2021.10.008.

13.Herpers B, Eppink B, James MI, et al. Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR×LGR5 bispecific antibody with efficacy in epithelial tumors[J]. Nat Cancer, 2022, 3(4): 418-436. DOI: 10.1038/s43018-022-00359-0.

14.He C, Lu F, Liu Y, et al. Emergent trends in organ-on-a-chip applications for investigating metastasis within tumor microenvironment: a comprehensive bibliometric analysis[J]. Heliyon, 2023, 10(1): e23504. DOI: 10.1016/j.heliyon.2023.e23504.

15.陈悦, 陈超美, 刘则渊, 等. CiteSpace知识图谱的方法论功能[J]. 科学学研究, 2015, 33(2): 242-253. [Chen Y, Chen CM, Liu ZY, et al. The methodology function of CiteSpace mapping knowledge domains[J]. Studies in Science of Science, 2015, 33(2): 242-253.] DOI: 10.3969/j.issn.1003-2053.2015.02.009.

16.Vlachogiannis G, Hedayat S, Vatsiou A, et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers[J]. Science, 2018, 359(6378): 920-926. DOI: 10.1126/science.aao2774.

17.van de Wetering M, Francies HE, Francis JM, et al. Prospective derivation of a living organoid biobank of colorectal cancer patients[J]. Cell, 2015, 161(4): 933-945. DOI: 10.1016/j.cell.2015.03.053.

18.Luo Z, Wang B, Luo F, et al. Establishment of a large-scale patient-derived high-risk colorectal adenoma organoid biobank for high-throughput and high-content drug screening[J]. BMC Med, 2023, 21(1): 336. DOI: 10.1186/s12916-023-03034-y.

19.Ooft SN, Weeber F, Dijkstra KK, et al. Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients[J]. Sci Transl Med, 2019, 11(513): eaay2574. DOI: 10.1126/scitranslmed.aay2574.

20.Yao Y, Xu X, Yang L, et al. Patient-derived organoids predict chemoradiation responses of locally advanced rectal cancer[J]. Cell Stem Cell, 2020, 26(1): 17-26. DOI: 10.1016/j.stem.2019.10.010.

21.Lyu T, Shen L, Xu X, et al. Patient-derived tumor organoids predict responses to irinotecan-based neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer[J]. Int J Cancer, 2023, 152(3): 524-535. DOI: 10.1002/ijc.34302.

22.Kim SC, Park JW, Seo HY, et al. Multifocal organoid capturing of colon cancer reveals pervasive intratumoral heterogenous drug responses[J]. Adv Sci (Weinh), 2022, 9(5): 2103360. DOI: 10.1002/advs.202103360.

23.Putker M, Millen R, Overmeer R, et al. Medium-throughput drug-and radiotherapy screening assay using patient-derived organoids[J]. J Vis Exp, 2021, (170): e62495. DOI: 10.3791/62495.

24.Mo S, Tang P, Luo W, et al. Patient‐derived organoids from colorectal cancer with paired liver metastasis reveal tumor heterogeneity and predict response to chemotherapy[J]. Adv Sci (Weinh), 2022, 9(31): e2204097. DOI: 10.1002/advs.202204097.

25.Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression[J]. Cancer Res, 2019, 79(18): 4557-4566. DOI: 10.1158/0008-5472.CAN-18-3962.

26.Li J, Chen D, Shen M. Tumor microenvironment shapes colorectal cancer progression, metastasis, and treatment responses[J]. Front Med (Lausanne), 2022, 9: 869010. DOI: 10.3389/fmed.2022.869010.